Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Receives Average Recommendation of “Moderate Buy” from Brokerages

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) has been assigned an average rating of “Moderate Buy” from the five analysts that are presently covering the company, MarketBeat.com reports. One analyst has rated the stock with a hold rating and four have issued a buy rating on the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $13.50.

A number of equities analysts have recently commented on AMRX shares. Weiss Ratings restated a “hold (c)” rating on shares of Amneal Pharmaceuticals in a research report on Wednesday, October 8th. JPMorgan Chase & Co. increased their target price on shares of Amneal Pharmaceuticals from $12.00 to $14.00 and gave the stock an “overweight” rating in a research note on Tuesday, September 16th. Barclays began coverage on shares of Amneal Pharmaceuticals in a research report on Monday, December 8th. They set an “overweight” rating and a $15.00 price target for the company. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $13.00 price target (up previously from $11.00) on shares of Amneal Pharmaceuticals in a report on Friday, October 31st.

Insider Transactions at Amneal Pharmaceuticals

In other Amneal Pharmaceuticals news, Director Ted C. Nark sold 50,000 shares of the firm’s stock in a transaction dated Monday, November 17th. The stock was sold at an average price of $11.72, for a total value of $586,000.00. Following the sale, the director owned 291,029 shares of the company’s stock, valued at $3,410,859.88. This trade represents a 14.66% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Nikita Shah sold 131,856 shares of Amneal Pharmaceuticals stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $11.92, for a total value of $1,571,723.52. Following the sale, the executive vice president owned 146,403 shares of the company’s stock, valued at approximately $1,745,123.76. This trade represents a 47.39% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 231,856 shares of company stock worth $2,743,724 over the last 90 days. Corporate insiders own 17.45% of the company’s stock.

Institutional Investors Weigh In On Amneal Pharmaceuticals

Several hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. grew its stake in Amneal Pharmaceuticals by 2.3% in the 3rd quarter. Vanguard Group Inc. now owns 17,954,973 shares of the company’s stock worth $179,729,000 after buying an additional 403,582 shares in the last quarter. Rubric Capital Management LP lifted its holdings in shares of Amneal Pharmaceuticals by 5.3% during the 3rd quarter. Rubric Capital Management LP now owns 12,334,941 shares of the company’s stock worth $123,473,000 after acquiring an additional 624,609 shares during the last quarter. Dimensional Fund Advisors LP grew its position in Amneal Pharmaceuticals by 2.5% in the third quarter. Dimensional Fund Advisors LP now owns 5,431,134 shares of the company’s stock worth $54,361,000 after acquiring an additional 133,764 shares in the last quarter. Nantahala Capital Management LLC increased its stake in Amneal Pharmaceuticals by 14.7% in the second quarter. Nantahala Capital Management LLC now owns 4,367,438 shares of the company’s stock valued at $35,333,000 after acquiring an additional 558,877 shares during the last quarter. Finally, BlackBarn Capital Partners LP raised its position in Amneal Pharmaceuticals by 19.6% during the second quarter. BlackBarn Capital Partners LP now owns 3,446,570 shares of the company’s stock valued at $27,883,000 after purchasing an additional 564,916 shares in the last quarter. 31.82% of the stock is currently owned by institutional investors.

Amneal Pharmaceuticals Stock Performance

Shares of NASDAQ AMRX opened at $12.91 on Thursday. Amneal Pharmaceuticals has a fifty-two week low of $6.68 and a fifty-two week high of $13.01. The stock has a market cap of $4.06 billion, a PE ratio of 645.82 and a beta of 1.36. The stock has a fifty day moving average of $11.81 and a 200-day moving average of $10.01.

Amneal Pharmaceuticals (NASDAQ:AMRX) last issued its earnings results on Thursday, October 30th. The company reported $0.17 EPS for the quarter, topping the consensus estimate of $0.12 by $0.05. The business had revenue of $784.51 million during the quarter. Amneal Pharmaceuticals had a negative return on equity of 185.60% and a net margin of 0.20%.Amneal Pharmaceuticals has set its FY 2025 guidance at 0.750-0.80 EPS. On average, sell-side analysts predict that Amneal Pharmaceuticals will post 0.53 EPS for the current year.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.